Background
Multi drug resistance (MDR1) gene polymorphisms can alter the drug transport function of p-glycoprotein and are often associated with resistance to antiretroviral therapy (ART) in HIV-1 patients. In this study, we investigated the association of single nucleotide polymorphisms in MDR1 gene (exon-21 and exon-26) with responsiveness to ART in HIV-1 patients.
Methods
Eighty HIV-1 infected drug naive patients who had atleast one viral load <150 copies/mL within six months of therapy and 21 healthy subjects were included. The HIV patients were categorized into viral responders (n=40) and non responders, two consecutive viral load ≥400 copies/mL after six months of ART (n=40).The genotype analysis of G2677T (GG/GT/TT in exon-21) and C3435T (CC/CT/TT in exon-26) was performed using PCR RFLP. Statistical analysis was carried out using chi-square test in SPSSver16.
Anzeige
Results
The proportion of CC, CT and TT-genotype among the healthy individuals was found to be 0.09, 0.52 and 0.38 whereas GT and TT-genotype was 0.61 and 0.38 respectively (No GG-genotype). Among HIV-1 patients, the distribution of CC, CT and TT-genotype between responders and non responders was (0.15 vs 0.07), (0.37 vs 0.50) and (0.50 vs 0.42) and GG, GT and TT was (0.12 vs 0.05), (0.30 vs 0.55) and (0.57 vs 0.40) respectively. Only the GT-genotype was significantly higher in non responders compared to responders (p=0.023).
Conclusion
The GT-genotype appears to predict poorer response to ART compared to other genotypes. Further studies could define more clearly the prognostic value of MDR1 gene polymorphisms in determining therapeutic response to ART.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.